The digital inhaler from Teva Pharmaceutical will bring relief to people with asthma.
For medical cannabis users, the biggest problem is a constant dose, says Syqe Medical CEO. After eight years of development and 50 million dollars of investment, Syqe® announces the launch of its new inhaler.
What is the cannabis bronchodilator?
In a world first, Israeli companies Teva Pharmaceutical Industries Ltd. and Tel Aviv-based Syqe Medical announced the signing of a distribution and cooperation agreement to commercialize medical cannabis in an inhaler. This is the first time that a large global pharmaceutical company has agreed to market a medical cannabis product, according to Syqe.
The effectiveness of medical cannabis treatment using a Syqe Inhaler has been demonstrated in several clinical trials. The results of these studies indicate that Syqe provides measured and consistent doses that are safe and effective for the treatment of chronic pain. Delivery of cannabis using the inhaler has also been found to reduce psychoactive effects by providing precise and effective low doses of THC, measured in micrograms. In addition to its clinical benefits, Syqe's bronchodilator has proven to be convenient and beneficial for both patients and physicians, who can control treatment with unprecedented precision, thus enabling robust and continuous clinical monitoring.
The objectives were to evaluate the use, usability, feasibility, satisfaction, and safety of the Syqe Inhaler Exo, a pharmacokinetic-validated metered dose inhaler device, in a cohort of hospitalized patients using cannabis for medical purposes. Licensed Medical Devices as part of their ongoing medical treatment.
The Syqe inhaler has been in use for over a year at Rambam Hospital in Haifa with the approval of the Israeli Ministry of Health. This makes it the first hospital in the world to prescribe cannabis as standard medical treatment.
The cannabis from which the tablets are produced is imported from the Dutch company Bedrocan. Syqe cartridges are preloaded with raw cannabis, with no additives or chemical manipulation. Raw, all-natural inflorescence only.
According to the company, 80% of cannabis patients consume their treatment with tobacco or vaporizers, to date there are no pharmaceutical standards for inhaled cannabis in the world. With the launch of this inhaler, it will now be possible to deliver precise, measurable and safe treatment.
The Syqe inhaler uses measured amounts of the molecules present in the cannabis flowers, thus allowing the control and the precision of the treatment, as is possible in any other medical treatment.
The dosage used by the inhaler is consistent, precise and tailored to the needs of each patient.
To date, Syqe has raised 33 million, including 20 million from Philip Morris International.